• PDF: Delivered by email usually within 4 to 8 UK business hours.

Belgium Pharmaceuticals and Healthcare Report Q3 2013

  • Publication Date:July 2013
  • Publisher:Business Monitor
  • Product Type: Report
  • Pages:107
  • ISBN:207098

Belgium Pharmaceuticals and Healthcare Report Q3 2013


Includes 3 FREE quarterly updates

BMI View:

We continue to expect a year-on-year (y-o-y) contraction in the value of the Belgian pharmaceutical market in 2013, as public expenditure continues to be challenged by the need for cost containment. While high per capita consumption of medicines continue to offer opportunities for researchbased pharmaceutical companies, risks will remain elevated, especially given the current economic backdrop.

Headline Expenditure Projections

- Pharmaceuticals: EUR5.96bn (US$7.57bn) in 2012 to EUR5.85bn (US$7.85bn) in 2013; -1.80% in local currency terms and +3.6% in US dollar terms. Local currency forecast virtually unchanged from Q213.
- Healthcare: EUR40.37bn (US$51.26bn) in 2012 to EUR41.20bn (US$55.21bn) in 2013; +2.1% in local currency terms and +7.7% in US dollar terms. Local currency forecast broadly unchanged from Q213.
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Industry Forecast 13
Pharmaceutical Market Forecast 13
Table: Belgium Pharmaceutical Sales, Historical Data and Forecasts, 2009-2017 14
Healthcare Market Forecast 15
Table: Belgium Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017 16
Table: Belgium Government Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017 16
Table: Belgium Private Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017 17
Prescription Drug Market Forecast 17
Table: Belgium Prescription Drug Market Indicators, Historical Data and Forecasts, 2009-2017 18
Patented Drug Market Forecast 19
Table: Belgium Patented Drug Market Indicators, Historical Data and Forecasts, 2009-2017 20
Generic Drug Market Forecast 20
Table: Generic Companies By Market Share, 2010 21
Table: Belgium Generics Drug Market Indicators, Historical Data and Forecasts, 2009-2017 23
OTC Medicine Market Forecast 23
Table: Belgium Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts, 2009-2017 25
Pharmaceutical Trade 25
Table: Belgium Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017 27
Table: Belgium Pharmaceutical Trade Data And Forecasts (EURmn), 2009-2017 27
Other Healthcare Data 27
Key Risks To BMI's Forecast Scenario 28
Macroeconomic Forecasts 30
Table: Belgium - Economic Activity 33
Industry Risk Reward Ratings 34
Europe Risk Reward Ratings 34
Belgium Risk/Reward Ratings 36
Market Overview 38
Industry Trends And Developments 40
Table: R&D Investment By Chemical & Life Science Industries, 2005-2010 47
Regulatory Development 50
Table: Reimbursements By Category, 2009 57
Table: Price Build-Up For OTC Medicines 60
Competitive Landscape 61
Table: Members Of AnGR, 2011 63
Table: Members Of OPHACO, 2011 65
Company Profile 67
UCB Pharma 67
Solvay (Abbott) 73
Janssen Pharmaceutica 76
Omega Pharma 79
Galapagos (GSK) 83
GlaxoSmithKline 87
Pfizer 90
Novartis 93
Sanofi 95
Merck & Co 97
Demographic Forecast 99
Table: Belgium's Population By Age Group, 1990-2020 ('000) 100
Table: Belgium's Population By Age Group, 1990-2020 (% of total) 101
Table: Belgium's Key Population Ratios, 1990-2020 102
Table: Belgium's Rural And Urban Population, 1990-2020 102
Glossary 103
Methodology 105
Pharmaceutical Expenditure Forecast Model 105
Healthcare Expenditure Forecast Model 105
Notes On Methodology 106
+44 20 8816 8548

Ask a question about Belgium Pharmaceuticals and Healthcare Report Q3 2013

Enter the characters you see in the picture below
Captcha